Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7165368 | 0.82 | NR3C2 (0.42) | CARM1PRMT6ALDH1A1MEN1KMT2A | |
| SCHEMBL3796858 | 0.77 | CARM1 (0.46) | CARM1PRMT6ALDH1A1MEN1KMT2A | |
| SCHEMBL11154452 | 0.77 | ALDH1A1 (0.36) | ALDH1A1MEN1KMT2AMAPTALOX15 | |
| SCHEMBL11151263 | 0.77 | EPHX1 (0.40) | ALDH1A1KDM4EHTTSMN1; SMN2CCR6 | |
| SCHEMBL3696096 | 0.75 | CARM1 (0.52) | CARM1PRMT6ALDH1A1MEN1KMT2A | |
| SCHEMBL236978 | 0.75 | CARM1 (0.52) | CARM1PRMT6ALDH1A1MEN1KMT2A | |
| SCHEMBL4611546 | 0.74 | PTGS2 (0.31) | ALDH1A1MEN1KMT2AMAPTALOX15 | |
| Hydrochloric Acid SCHEMBL1170216 | 0.73 | CARM1 (0.50) | CARM1PRMT6ALDH1A1MEN1KMT2A | |
| SCHEMBL24616539 | 0.72 | ROCK2 (0.42) | ALDH1A1MEN1KMT2AMAPTALOX15 | |
| SCHEMBL1425186 | 0.72 | KDM4E (0.52) | CARM1PRMT6ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020218680-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DIODE USING SAME | 두산솔루스 주식회사 | 2020-10-29 | — | — | WO | disclosed |
| WO-2009124627-A1 | FLUORINE DERIVATIVES FOR ORGANIC ELECTROLUMINESCENCE DEVICES | MERCK PATENT GMBH (DE) | 2009-10-15 | — | — | WO | disclosed |
| EP-1626717-A4 | BENZIMIDAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO INC (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| EP-1626717-A2 | BENZIMIDAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | Merck & Co., Inc. (US) | 2006-02-22 | — | — | EP | disclosed |
| US-20050256175-A1 | Novel glucagon antagonists/inverse agonists | LAU JESPER | 2005-11-17 | — | — | US | disclosed |
| EP-1183229-B1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK AS (DK) | 2005-10-26 | — | — | EP | disclosed |
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2005-09-15 | — | — | US | disclosed |
| US-6881746-B2 | Glucagon antagonists/inverse agonists | NOVO NORDICK A/S (DK) | 2005-04-19 | — | — | US | disclosed |
| EP-1519723-A1 | NOVEL GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2005-04-06 | — | — | EP | disclosed |
| US-6503949-B1 | Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity | NORO NORDISK A/S (DK) | 2003-01-07 | — | — | US | disclosed |
| US-20020187982-A1 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2002-12-12 | — | — | US | disclosed |
| WO-2002040444-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-05-23 | — | — | WO | disclosed |
| WO-2002040446-A1 | GLUCAGON ANTAGONIST/INVERSE AGONIST | NOVO NORDISK A/S (DK) | 2002-05-23 | — | — | WO | disclosed |
| WO-2002040445-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-05-23 | — | — | WO | disclosed |
| EP-1183229-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000069810-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2000-11-23 | — | — | WO | disclosed |
| US-5395971-A | Molybdenum-catalyzed amination of olefins | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 1995-03-07 | — | — | US | disclosed |
| US-5349109-A | Molybdenum-catalyzed amination of olefins | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 1994-09-20 | — | — | US | disclosed |
| US-4101575-A | FUNGICIDES, BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1978-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256175-A1 | Novel glucagon antagonists/inverse agonists | GLP1R, GCGR, GIPR | CARM1 4825/4885PRMT6 3954/4885ALDH1A1 4836/4885 |
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | CARM1 4344/4885PRMT6 3696/4885ALDH1A1 3968/4885 |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | GLP1R, GPR119, GCGR | CARM1 4344/4885PRMT6 3696/4885ALDH1A1 3968/4885 |
| US-20020187982-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | CARM1 4299/4885PRMT6 3619/4885ALDH1A1 3770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.